Obio Technology (Shanghai) Corp., Ltd. (SHA:688238)
7.09
-0.06 (-0.84%)
At close: Feb 13, 2026
SHA:688238 Revenue
Obio Technology (Shanghai) Corp. had revenue of 60.50M CNY in the quarter ending September 30, 2025, a decrease of -14.56%. This brings the company's revenue in the last twelve months to 244.64M, down -2.80% year-over-year. In the year 2024, Obio Technology (Shanghai) Corp. had annual revenue of 248.15M with 21.16% growth.
Revenue (ttm)
244.64M
Revenue Growth
-2.80%
P/S Ratio
18.27
Revenue / Employee
353.52K
Employees
678
Market Cap
4.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 248.15M | 43.34M | 21.16% |
| Dec 31, 2023 | 204.81M | -86.50M | -29.69% |
| Dec 31, 2022 | 291.30M | 36.36M | 14.26% |
| Dec 31, 2021 | 254.95M | 112.18M | 78.57% |
| Dec 31, 2020 | 142.77M | 79.85M | 126.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.69B |
| Hefei Lifeon Pharmaceutical | 1.47B |
| Pulike Biological Engineering | 1.10B |
| Boji Medical Technology | 770.19M |
| Zhejiang Shouxiangu Pharmaceutical | 642.66M |
| Assure Tech (Hangzhou) | 462.72M |
| Innovita Biological Technology | 430.96M |
| Guanhao Biotech | 392.83M |